Key points for investors:
- Strong Q1 performance: sales +5% to >£7.6bn, specialty medicines +14%, Shingrix quarterly record (>£1bn, +20%), core operating profit +10%, EPS +9%, cash generation £1.4bn and a Q1 dividend of 17p. Full-year guidance confirmed.
- Commercial drivers: Shingrix, oncology (Jemperli), HIV portfolio (Dovato, Cabenuva, Apretude) and specialty launches (Nucala COPD, Exdensur, Blenrep) are the main growth engines. Nucala showing strong COPD uptake (c.45% market share in US COPD new patients); Exdensur early uptake limited by J-code access (expected early July); Blenrep gaining community adoption in multiple myeloma.
- HIV franchise: HIV sales +10% (Dovato strength). Ongoing development of long-acting assets — 3x yearly Cabenuva (CUATRO on track; potential 2028 launch) and 3x yearly Apretude (registrational data H2 2026, launch H1 2027). Work on twice-yearly injectables continues with Phase II/III planning toward end-of-decade launches.
- Pipeline acceleration: Management is prioritizing and accelerating late‑stage programs (multiple Phase III starts/reads in H2), including ADCs (Ris-Rez, Mo-Rez), velzatinib (GIST), camlipixant (refractory chronic cough), Exdensur (EGPA), and efimosfermin (MASH). The company reports positive Phase III headline data for bepirovirsen (functional cure in chronic HBV) with FDA breakthrough designation and a PDUFA date of 26 Oct 2026.
- Business development and portfolio moves: Recent acquisitions (ozureprubart, HS235, 35Pharma) to bolster respiratory, inflammation and cardiopulmonary programs. RAPT Therapeutics acquisition and other BD investment continue. Expected cash outflows for 35Pharma (~$950m in Q2) but portfolio monetizations (ViiV special dividend, Rockville sale, linerixibat out-licensing) to improve net debt; net debt ~1.4x EBITDA.
- Financial positioning & capital allocation: Continued R&D investment, SG&A disciplined, productivity benefits expected H2 weighted. Share buyback underway and on track. Guidance confirmed with half‑year phasing notes: vaccines and Gen Med phasing and Trelegy facing tough comps and Medicare co-pay headwinds early in the year.
- Risks / near-term execution items: access and coding (J-code) for Exdensur in US; continuing China rollout dynamics for Shingrix (stock/demand phasing); diagnosis and testing rates for hepatitis B could limit near-term uptake of bepirovirsen despite regulatory designations; Medicare redesign and copay changes affecting Trelegy US growth in Q1.
- Investor takeaway: Management is focused on converting an accelerating late-stage pipeline and recently acquired assets into mid-term commercial growth while maintaining disciplined capital allocation — watch upcoming H2 readouts (multiple Phase III results), EASL data and bepirovirsen regulatory milestones, the Q2 portfolio/pipeline update, and progress on US coding/access for Exdensur.
Sign In
Buy GLAXF
